| Code | Display | Definition |
| DE109 | Birth dose | Indicates if the client received a dose within 24 hours of birth. Whether a birth dose is counted as part of the primary series will depend on the antigen. |
| DE103 | Type of dose | The type of dose in a series that the client received |
| DE104 | Primary series | Indicates that the client received the primary vaccination series of a product/antigen. This is also applicable for antigens with one dose. |
| DE105 | Dose 0 | Indicates that the client received a dose of a product/ antigen within 24 hours of birth. This dose is not a part of the primary vaccination series. |
| DE106 | Supplementary dose | Indicates that the client received a supplementary dose of a product/antigen |
| DE107 | Booster dose | Indicates that the client received booster dose of a product/antigen |
| DE8 | Completed the primary vaccination series | Indicates if the client has completed the primary vaccination series of a product/antigen. If the client has not yet completed their primary series, it means they may be expected to receive more doses to complete their vaccination regimen for the respective product/antigen. |
| DE102 | Completed the booster series | Indicates if the client has completed the booster series of a product/antigen |
| DE81 | Date when primary vaccination series was completed | The date when the client completed the primary vaccination series (per product/antigen) |
| DE10 | HIV status | The current human immunodeficiency virus (HIV) status of the client |
| DE11 | HIV-positive | The client is known to be HIV positive |
| DE12 | HIV-negative | The client is known to be HIV negative |
| DE13 | Unknown | The client's HIV status is unknown |
| DE15 | Preterm birth | The infant was preterm; the mother gave birth to the infant when gestational age was less than 37 weeks |
| DE16 | Immunocompromised | The client is known to be immunocompromised. This means the client has a weakened immune system and having a reduced ability to fight infections and other diseases |
| DE17 | Currently on ART | The client is currently receiving antiretroviral therapy (ART) |
| DE84 | Type of TB infection test performed | The type of TB infection test performed |
| DE85 | IGRA | Interferon-gamma release assay (IGRA) |
| DE86 | TST | Tuberculin skin test (TST) |
| DE87 | TB infection test result | Records the result of the TB infection test |
| DE88 | Positive | Test result was positive |
| DE89 | Negative | Test result was negative |
| DE93 | Immunologically stable | The client is living with HIV and is immunologically stable with CD4 count or percentage above a minimum as defined in the HIV guidelines |
| DE94 | Clinically well | The client is living with HIV and is clinically well, as defined in HIV guidelines and WHO clinical staging |
| DE29 | Birth weight in grams | Represents the client's birth weight value measures in grams |
| DE35 | Type of polio dose | The type of the polio vaccine dose administered to the client |
| DE36 | IPV | Inactivated poliovirus vaccine (IPV) |
| DE37 | bOPV | Bivalent oral poliovirus vaccine (bOPV) |
| DE92 | Severely immunosuppressed | The client is known to be severely immunosuppressed |
| DE49 | ART start date | The date on which the client started or restarted antiretroviral therapy (ART) |
| DE96 | High risk of pneumococcal infection | The client is at high risk for pneumococcal infection because of underlying medical conditions (i.e. HIV infection or sickle-cell disease) |
| DE52 | Type of JE dose | The type of Japanese encephalitis (JE) vaccine dose administered to the client |
| DE53 | Inactivated Vero cell-derived vaccine | Inactivated Vero cell-derived Japanese encephalitis (JE) vaccine type |
| DE54 | Live attenuated vaccine | Live attenuated Japanese encephalitis (JE) vaccine type |
| DE55 | Live recombinant vaccine | Live recombinant Japanese encephalitis (JE) vaccine type |
| DE56 | Type of TBE dose | The type of tick-borne encephalitis (TBE) vaccine dose administered |
| DE57 | FSME-Immun | FSME-Immun vaccine product, which is an inactivated whole-virus vaccine for tick-borne encephalitis (TBE) |
| DE58 | Encepur | Encepur vaccine product, which is an inactivated viral vaccine for tick-borne encephalitis (TBE) |
| DE59 | TBE-Moscow | TBE-Moscow vaccine product, which is a vaccine for tick-borne encephalitis (TBE) |
| DE60 | EnceVir | EnceVir vaccine product, which is a vaccine for tick-borne encephalitis (TBE) |
| DE61 | Type of typhoid dose | The type of typhoid vaccine dose administered to the client |
| DE62 | Typbar-TCV | Typbar-TCV vaccine |
| DE63 | ViPS | Vi polysaccharide (ViPS) vaccine |
| DE64 | Ty21a | Ty21a vaccine |
| DE65 | Type of cholera dose | The type of cholera vaccine dose administered to the client |
| DE66 | WC vaccine | Killed whole cell (WC) only cholera vaccine |
| DE67 | WC-rBS vaccine | Vaccine contains a mixture of the recombinant B subunit (rBS) of cholera toxin plus killed whole cell (WC) |
| DE68 | Type of meningococcal dose | The type of meningococcal vaccine dose administered to the client |
| DE69 | MenA conjugate vaccine (5µg) | Monovalent serogroup A (MenA) conjugate vaccine (5µg) vaccine |
| DE70 | Monovalent MenC conjugate | Monovalent MenC conjugate vaccine |
| DE71 | Quadrivalent conjugate | Quadrivalent conjugate (A,C,W135,Y-D and A,C,W135,Y-CRM) vaccines |
| DE97 | Polysaccharide vaccine | Polysaccharide vaccines not including polysaccharide-protein conjugate vaccines |
| DE72 | Age in months when client received first meningococcal dose | The age in months when client received their first meningococcal dose |
| DE73 | Type of hepatitis A dose | The type of hepatitis A vaccine dose administered to the client |
| DE74 | Live attenuated hepatitis A vaccine | Live attenuated hepatitis A vaccine |
| DE75 | Inactivated hepatitis A vaccine | Inactivated hepatitis A vaccine |
| DE99 | Type of hepatitis B dose | The type of hepatitis B vaccine dose administered to the client |
| DE100 | Hepatitis B monovalent vaccine | Hepatitis B monovalent vaccine |
| DE101 | Hepatitis B combination vaccine | Hepatitis B combination vaccine |
| DE76 | VNA level | Vaccine-induced neutralizing (VNA) antibody level. It is a measured as a serum antibody concentration amount observed from the result of the concentrated, purified cell culture and embryonated egg-based rabies vaccines (CCEEV) |
| DE98 | Risk of occupational exposure to rabies virus | Professional at risk of occupational exposure to rabies virus, particularly animal health-care workers. Also considered for medical professionals who regularly provide care to persons with rabies. |
| DE77 | Dengue serostatus | Indicates the result of a serological test determining whether the client has antibodies against the dengue virus |
| DE110 | Positive | The client has detectable antibodies against the dengue virus, suggesting past exposure or vaccination |
| DE111 | Negative | The client does not have detectable antibodies, indicating no previous exposure or vaccination against the dengue virus |
| DE112 | Unknown | The client's dengue serostatus is unknown |
